Swartz Roger B Seeks Patent for mRNA, Episomal and Genomic Integrated Lentiviral and Gammaretroviral Vector Expression of Dimeric Immunoglobulin a and Polymeric Immunoglobulin a to Enable Mucosal and Hematological Based Immunity/Protection Via Gene Therapy for Allergens, Viruses, HIV , Bacteria, Pneumonia, Infections, Pathology Associated Proteins, Systemic Pathologies, Cancer, Toxins and Unnatural Viruses. Car Engineered and Non-Car Engineered Immune Cell Expression of Dimeric Immunoglobulin a and Polymeric Immunoglobulin A.
| Published date | 04 February 2022 |
| Publication title | Global IP News (India) |
U.S. Patent and Trademark Office has released the abstract. According to the abstract, "The present invention contemplates mRNA, episomal and retroviral genomic gene therapy based short-term, intermediate or long-term vaccine, immunization, immune protection or cancer--that can also be administered as a retroviral genomic gene therapy both in vivo and ex vivo--method to provide epithelial and hematological protection to humans to protect against cancer especially carcinomas, pandemic and non-pandemic viruses, bacterial infections, allergens or the cause of allergic reactions, systemic pathological conditions, cancer and anti-biowarfare agents (e.g. natural and unnatural viruses and toxins) where mucosal immunity and for some diseases hematological immunity is achieved through mRNA, episomal or genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A1 (dIgA1), dimeric immunoglobulin A2 (dIgA2) and engineered variants. Additionally, in some embodiments a method to agglutinate cancers including carcinomas and hematological cancers to prevent metastasis with polymeric immunoglobulin A and dimeric immunoglobulin A and engineered variants. The present invention provides methods, immunoglobulin compositions and vector constructs to express potent immunoglobulins that are derived from human blood of a human currently infected with, affected by, exposed to or recovered from any of a wide range of allergens or the cause of allergic reactions, pathogens (including, viruses, virus mutants, bacterial infections and fungi) and systemic pathological ailments (including cancer and other disorders), developed from phage display technology or mice or other non-human vertebrates with engineered immune systems or humanized immune systems, transgenic mice or chimeric antibodies a fusion of non-human vertebrates (e.g. mouse or rabbit), mouse antibody V-regions, human antibodies. The immunoglobulin compositions include the heavy chain variable, diversity and joining (VDJ or Variable Heavy Region genes) segment immunoglobulin DNA and/or polypeptide sequence from humans identified to have therapeutically relevant affinity immunoglobulins against the antigen, protein or proteins of interest and either to use the exact immunoglobulin heavy chain and light chain polypeptide sequences identified from the B-cell that produced them or to modify or engineer some of the immunoglobulin heavy chain and light chain constant domains to modulate effector...
To continue reading
Request your trial